Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)

Launched by UNIVERSITY OF CHICAGO · Nov 22, 2024

Keywords

ClinConnect Summary

The PARADISE clinical trial is studying a treatment option for men with prostate cancer called prostate ablation. This method aims to destroy cancer cells in a way that is less invasive than traditional surgeries, which can help reduce side effects and improve recovery. The trial is collecting information on men who have been diagnosed with prostate cancer and are undergoing this type of treatment. The goal is to build a database that helps researchers understand the long-term effectiveness and side effects of prostate ablation.

To participate in this study, men must be at least 22 years old and have a confirmed diagnosis of prostate cancer. They should be scheduled to have or already have undergone prostate ablation using specific techniques like cryotherapy or high-intensity focused ultrasound. Participants won't face any additional risks from being part of this study, as the information collected will only come from their existing medical records. This research is important for improving how we treat prostate cancer and ensuring that patients have better outcomes with fewer complications.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Male sex
• • ≥22 years of age
• • Histologic diagnosis of prostate cancer
• • Scheduled to undergo or have already undergone ablation of the prostate as part of routine clinical care or any ongoing clinical trials
• • Prostate ablation performed with any of the following energy sources: cryotherapy, high-intensity focused ultrasound, irreversible electroporation, laser, microwave, radiofrequency ablation, or photodynamic therapy. Newer methods and instrumentation continue to be developed to ablate tissue, and these energy sources can be entered into the registry as clinical use begins
• Exclusion Criteria:
• • Under 21 Years of age.